Navigation Links
CVBT Doses First Patient in its Phase II Clinical Trial for Severe Coronary Heart Disease
Date:11/25/2008

p>

CVBT-141H contains and active ingredient -- human Fibroblast Growth Factor-1 (FGF-1). FGF-1 is a natural human protein that stimulates angiogenesis in the affected tissue or organ. Angiogenesis refers to the growth of new blood vessels that may help those suffering from coronary heart disease by increasing blood flow to ischemic tissue or tissue that has been damaged from lack of oxygen and nutrients from blood supply. By providing blood flow to the damaged regions of the heart, the tissues can regenerate.

About Coronary Heart Disease

According to the American Heart Association's 2007 Update, among adults age 20 and older, an estimated 15.8 million Americans (2004) suffer from coronary heart disease (CHD). CHD is the single largest killer of Americans. According such Update, the estimated direct and indirect cost of CHD in the United States for 2007 is $151.6 billion.

About CardioVascular BioTherapeutics, Inc.

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company is pursuing two FDA-authorized clinical programs in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. Clinical research is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit http://www.cvbt.com.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding attaining maximum funding levels of clinical d
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Trius Doses First Patient in Antibacterial Phase 2 Trial
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
4. Video: Resveratrol-based Nutriceutical (Longevinex(R)) Induces Favorable Changes on Gene Expression in Mouse Heart At Doses 17-320 Times Lower Than Prior Studies
5. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
6. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
7. NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
8. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
9. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
10. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
11. Peregrine Pharmaceuticals Doses First Patient in Clinical Trial of Bavituximab in HCV Patients Co-Infected With HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept. 23, 2014 CASI Pharmaceuticals, ... dedicated to the acquisition, development and commercialization of innovative ... the global market with a primary focus on ... Rajesh C. Shrotriya , MD, Chairman and Chief Executive ... Directors.  The appointment was made in connection with the ...
(Date:9/23/2014)...  As physicians seek information about drugs today, ... learn about new therapies or ask questions of ... report by global sales and marketing consultants at ... a customized mix of digital media and visits ... engage with physicians. And, productive engagement with physicians ...
(Date:9/23/2014)... 23, 2014 Avillion LLP, ... appointment of Jarrod Longcor as Chief ... responsible for structuring, negotiating and executing successful strategic ... as providing management and strategic leadership to the ... leadership team. Mr Longcor brings to ...
Breaking Medicine Technology:CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 2CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 3CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 2As sales reps see doors close for in-person visits with physicians, digital doors open communication 3As sales reps see doors close for in-person visits with physicians, digital doors open communication 4As sales reps see doors close for in-person visits with physicians, digital doors open communication 5Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... Mont., May 8, 2012  Bacterin International Holdings, Inc. ... in the development of revolutionary bone graft material ... third national GPO contract, a three-year agreement with ... and contracting company.  The agreement provides Bacterin,s full ...
... Heska Corporation (NASDAQ: HSKA ), a provider ... announced that its Board of Directors has declared a cash ... payment will be distributed on July 10, 2012 to stockholders ... to pay a regular quarterly dividend of $0.10 per share ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4Heska Announces Quarterly Dividend of $0.10 Per Share 2
(Date:9/23/2014)... Given the nondiscretionary nature of ... and Vegetable Markets industry is generally stable; ... operators over the five years to 2014. Furthermore, ... demographic trends, including a focus on healthy eating ... fruit and vegetable consumption declined at an annualized ...
(Date:9/23/2014)... will present the results of their cancer research ... Madrid. , Joint Symposium: ESMO-ASCO: The Evolution ... 29, 11:00 AM - 12:30 PM, Room: Granada, ... Platforms support new forms of cancer clinical research? ... Proffered Paper session: Melanoma and other skin ...
(Date:9/23/2014)... 2014 The "area under the curve of oxygen ... approach to monitoring blood oxygen levels during procedures using ... & Analgesia . , The AUC Desat provides ... lowbut also on the depth, duration, and rate of ... Paul Niklewski, PhD, of University of Cincinnati and colleagues ...
(Date:9/23/2014)... million in supplemental funding to bolster the research of ... preclinical and clinical studies. , This investment encourages researchers ... for considering sex as a fundamental variable in research. ... can obscure key findings related to sex that could ... in greater awareness of the need to study both ...
(Date:9/23/2014)... cancer in their lifetime and 20 per cent of ... researchers from the University of Leicester has helped Avacta ... system for diagnosing lymphoma in dogs in the early ... cLBT (canine lymphoma blood test), this is the first ... status of a dog after undergoing chemotherapy. , ...
Breaking Medicine News(10 mins):Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Fruit & Vegetable Markets in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:EORTC presentations at ESMO 2014 Congress 2Health News:EORTC presentations at ESMO 2014 Congress 3Health News:New measure provides more data on oxygen levels during sedation 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 2Health News:New supplemental awards apply sex and gender lens to NIH-funded research 3Health News:New hope for beloved family pets 2
... -- Primary school children cannot accurately estimate the speed of ... a new study. "This is not a matter of ... visual detection mechanisms," John Wann, lead researcher and a professor ... of London, said in a university news release. ...
... shows the NSAID Celebrex may help prevent some non-melanoma ... actinic keratoses lesions and are at high risk for ... of Alabama at Birmingham dermatologist and the study,s lead ... of celecoxib as a chemo-preventive agent for actinic keratoses. ...
... what might be one of the world,s first medicinal body ... have successfully implanted an experimental device in the throat of ... ability to swallow. The device, which could offer an effective ... controlled by pulling on a tiny metal pin that extends ...
... November 30, 2010The Council for Responsible Nutrition (CRN), the ... National Academy of Sciences Institute of Medicine,s (IOM) newly-released ... vitamin D "a modest step in the right ... and positive research that has consistently supported the need ...
... TUESDAY, Nov. 30 (HealthDay News) -- Acupuncture alters the ... finding that suggests the traditional Chinese treatment can effectively ... researchers used functional MRI scans to measure brain activity ... a device fitted to their left ankle. The researchers ...
... sleep apnea (OSA), a sleep disorder associated with obesity, ... arteries, according to a study presented today at the ... (RSNA). "Our study reveals that individuals with obstructive ... of atherosclerosis that puts them at risk for impaired ...
Cached Medicine News:Health News:Kids Can't Accurately Judge Speed of Approaching Cars: Study 2Health News:Celebrex may help prevent some non-melanoma skin cancers 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 2Health News:UC Davis surgeons test innovative device in patient with swallowing disorder 3Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 2Health News:CRN reacts to Institute of Medicine DRI recommendations for vitamin D 3Health News:People with sleep apnea at higher risk for aggressive heart disease 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: